Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies (NASDAQ: BSGM) announced the acceptance of its abstract titled 'Computational Reconstruction of Electrocardiogram Lead Placement' for presentation at the 2020 Computing in Cardiology Conference (CinC). The research introduces a novel algorithm that reconstructs ECG lead placements using signal correlations, enhancing the classification of cardiac conditions. Co-authored by experts from Reified LLC and Mayo Clinic, the method may unlock new clinical applications. The presentation will occur virtually on September 15, 2020.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced a conference call and webcast on September 15, 2020, to discuss the randomized, blinded data from the PURE EP 2.0 Clinical Study during atrial fibrillation ablation procedures at St. David’s Medical Center, Austin, Texas. The presentation will include key findings and a commercial market update. A replay of the call will be available for two weeks post-event. BioSig specializes in biomedical signal processing technology aimed at improving signal fidelity in electrocardiograms.
BioSig Technologies (Nasdaq: BSGM) announced a Phase 2 clinical trial of merimepodib in conjunction with remdesivir for hospitalized COVID-19 patients requiring advanced respiratory support. The randomized, double-blind study is being conducted at five sites across the U.S., directed by Dr. Andrew Badley from Mayo Clinic. The trial evaluates the safety and efficacy of merimepodib, which has shown in vitro antiviral activity against SARS-CoV-2. A conference call is scheduled for September 22, 2020, to discuss trial insights and future plans.
BioSig Technologies, Inc. (Nasdaq: BSGM) will host a conference call on September 15, 2020, at 11:00 AM ET to discuss the initial results from the PURE EP 2.0 Clinical Study, focusing on atrial fibrillation ablation procedures. The blinded, randomized data was presented at ESC Congress 2020 and collected at St. David’s Medical Center in Austin, Texas. The PURE EP System aims to enhance ECG and intra-cardiac signal fidelity. A replay will be available starting September 15. For further details, visit www.biosig.com.
BioSig Technologies (NASDAQ: BSGM) will present at the 12th Annual LD 500 Conference on September 2, 2020, at 11:40 AM ET. The presentation, led by Kenneth L. Londoner, will highlight the company’s advancements, including the installation of its PURE EP™ System at Massachusetts General Hospital. Additionally, BioSig's subsidiary, ViralClear Pharmaceuticals, is conducting a Phase 2 clinical study for the COVID-19 treatment merimepodib in combination with remdesivir. Attendees can register for the event through the provided links.
BioSig Technologies, Inc. (NASDAQ: BSGM) is set to present at the 12th Annual LD 500 Conference on September 2, 2020, at 11:40 AM ET. Kenneth L. Londoner, the Company's Chairman and CEO, will discuss recent developments, including the installation of the PURE EP™ System at Massachusetts General Hospital as part of a clinical study. Additionally, BioSig’s subsidiary, ViralClear Pharmaceuticals, is enrolling patients for a Phase 2 clinical study of merimepodib in combination with remdesivir for COVID-19 treatment.
BioSig Technologies' subsidiary, ViralClear Pharmaceuticals, has appointed Professor Angus Dalgleish to its Scientific Advisory Board, enhancing its expertise in antiviral drug development. ViralClear is currently conducting Phase 2 trials of merimepodib, a treatment for COVID-19, which has shown strong antiviral activity against SARS-CoV-2 in cell cultures. The Scientific Advisory Board aims to oversee drug discovery and address emerging viral infections. This strategic addition reflects the company's commitment to combating COVID-19 and strengthens its leadership team.
BioSig Technologies (Nasdaq: BSGM) announced the appointment of Dr. Michael J. Sofia to its subsidiary ViralClear Pharmaceuticals' Scientific Advisory Board. Dr. Sofia, an esteemed researcher with over 110 publications and a pivotal inventor of sofosbuvir, aims to leverage his extensive experience in antiviral drug development to advance ViralClear's COVID-19 treatment, merimepodib. Currently in Phase 2 trials, merimepodib shows promise against SARS-CoV-2 and previously completed 12 clinical trials with a strong safety profile.
BioSig Technologies (BSGM) announced the installation of its PURE EP™ System at Massachusetts General Hospital as part of an expanded clinical study. Under the leadership of Dr. Moussa Mansour, the evaluation will advance the Company's efforts in cardiac signal processing. This follows ongoing studies at Texas Cardiac Arrhythmia Research Foundation and Mayo Clinic. The Company aims to tap into the recovering atrial fibrillation market, emphasizing the significance of patient cases for healthcare outcomes.
BioSig Technologies, Inc. (BSGM), a medical technology firm, has secured a Commercial and Government Entity (CAGE) code from the Systems for Award Management (SAM). This code enables BioSig and its subsidiary, ViralClear, to engage in business with U.S. government agencies and pursue government contracts effectively.
The CAGE code positions BioSig to apply for government contracts and assistance programs, potentially opening new revenue streams for the company.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
